DRUG STUDY

DRUG NAME ACTIONS SIDE EFFECTS ADVERSE INDICATI CONTRAINDIC NURSING

EFFECTS ONS ATIONS RESPONSIBIL
ITIES
GENERIC Inhibits cell-  Thrush Gh diarrhea. Skin Intra-  Contraindicat  Dosage is
NAME: Unasyn wall  Irritation Of pain at injection abdominal, ed in patients expressed
(ampicillin synthesis The Stomach site, gynecologic hypersesitive as total
sodium/sulbactam Or Intestines
during thrombophelebiti , and skin- to drug or drug. Each
sodium)  Headache
bacterial s, rah, urticaria. structure other vial
BRAND  Loose Stools
multiplication  Diarrhea Others infections penicillins, in containts
NAME: Ampi,
. hypersensitivity caused by those with 2:1 ratio of
Omnipen,  Itching
Penglobe, and
reactions. susceptible sensitivity to ampicillin
 A Skin Rash
Principen. strains multiple sodium to
 Trouble
Breathing allergens, and sulbactam
DOSAGE:  Anaphylaxis in those with sodium.
1.5g (ampicillin  A Serum monocleosis  In patient
 Dosage
1g/sulbactam 0.5g) Sickness because of with
adjustme
3g (ampicillin Reaction high risk of impaired nts
2g/sulbactam 1g)  Constipation maculopapula renal necessary
15g (ampicillin
 Difficulty r rash. function, in
10g/sulbactam 5g)
Sleeping  Contraindicat decreas patients
 Nausea ed in patients frequency of with renal
CAPSULE:  Vomiting impairme
with a history administrati
nt.
of cholestatic on.
Route: PO Patients
Ketorolac: jaundice or  Monitor LFT with renal
 headache hepatic results impairme
 dizziness dysfunction during nt should
 drowsiness receive
associated therapy,
 diarrhea
with especially in the
 constipation
usually
 gas ampicillin- patients with
 sores in the mouth
recomme
sulbactam impaired nded
 DRUG STUDY
 sweating injection liver
dose but
function.
these
 If large doses
doses are should be
given or if given less
therapy is frequently
prolonged, than
usual.
bacterial or
 Drug
fungal
induced
superinfectio
liver
n may
injury
occur,
such as
especially in
cholestati
elderly,
c hepatitis
debiliated,
and
or
jaundice
immunosupp
have
ressed
been
patients.
associate
 Watch for
d with the
signs and
use of
symptoms of
ampicillin/
hypersensiti
sulbactam
vity, such as
. Patients
erythematou
should be
s
advised
maculopapul
to contact
ar rash,
their
urticaria and
doctor if
anaphylaxis.
signs and
 DRUG STUDY
 Monitor for symptoms
CDAD, of hepatic
which can disease
be fatal. develop.
Antibiotic  If a
may need to hypersens
be stopped itivity
and other reaction
treatment occurs,
begun. the
clinician
should
discontinu
e therapy
and
alternativ
e
treatment
initiated
 If CDAD
is
suspected
or
confirmed
, ongoing
antibiotic
use not
directed
against C.
difficile
DRUG STUDY
may need
to be
discontinu
ed.
Appropria
te fluid
and
electrolyt
e
managem
ent,
protein
suppleme
ntation,
antibiotic
treatment
of C.
difficile,
and
surgical
evaluatio
n should
be
instituted
as
clinically
indicated.
DRUG STUDY